PCRX
NASDAQPacira BioSciences Inc.
News · 26 weeks88+29%
2025-12-142026-06-07
Mix5290d
- Other25(48%)
- SEC Filings15(29%)
- Insider8(15%)
- Earnings2(4%)
- Leadership2(4%)
Latest news
25 items- INSIDERSenior Vice President, Finance Riker Lauren covered exercise/tax liability with 3,187 shares, decreasing direct ownership by 4% to 68,399 units (SEC Form 4) to satisfy withholding tax4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Medical Officer Slonin Jonathan covered exercise/tax liability with 4,728 shares, decreasing direct ownership by 2% to 218,912 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Administrative Officer Williams Kristen sold $228,468 worth of shares (10,259 units at $22.27) as part of a pre-agreed trading plan and covered exercise/tax liability with 8,528 shares, decreasing direct ownership by 10% to 167,062 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingElection of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward MomentumLeading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not WarrantedBRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. Ahea
- SECSEC Form 144 filed by Pacira BioSciences Inc.144 - Pacira BioSciences, Inc. (0001396814) (Subject)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Ca
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director NomineesBRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC ("Glass Lewis") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card ahead of the Company's 2026 Annual Meeting of Stockholders (the "Annual
- PRDOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTIONPACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATEDOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AND MINIMIZING THE POTENTIAL BUSINESS-DESTROYING CONSEQUENCES OF ANOTHER LEGAL LOSS, CONSTITUTING GROSS NEGLIGENCEDOMA CONTENDS THE BOARD IS REFUSING TO EXPLORE A SALE BECAUSE DIRECTORS DO NOT WANT TO LOSE THEIR JOBS, PUTTING THEIR INTERESTS AHEAD OF SHAREHOLDERSMIAMI, May 28, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual") is a fundamentals-based, value-oriented asset management firm, which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns ap
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified NomineesClarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication with important facts stockholders should know to help protect their Pacira investment. The complete text of the letter mailed to stockholders is as follows: May 27, 2026 Dear Pacira Stockholders, A
- PRAfter Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
- PRPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder ArthroplastyFindings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from a real-world study evaluating outcomes associated with the use of EXPAREL® (bupivacaine liposome injectable suspension) following outpatient total shoulder arthroplasty (TSA) in Medicare Advantage patients. The study was presented at ISPOR—The Professional Society for Health Economics and Out
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property StrategyUrges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira's intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 recent inaccurate statements: DOMA's claims demonstrate a fundamental lack of understanding of Pacira's business, intellectual p
- PRA Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
- PRA LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLCFRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLOWING MANAGEMENT AND THE BOARD TO FURTHER ENRICH THEMSELVES WITH TENS OF MILLIONS OF DOLLARS IN PAYOUTS?EXPAREL IS THE COMPANY'S CORE ASSET; WE BELIEVE BOARD MISMANAGEMENT OF THE PATENT RISK AMOUNTS TO GROSS NEGLIGENCE AND A FAILURE OF THE DUTY OF CARESHAREHOLDERS SHOULD DECIDE IF THE SALE PRICE THE COMPANY FINDS THROUGH A DISCIPLINED, BOARD‑SUPERVISED PROCESS IS ADEQUATE AND IN THE BEST INTERESTS OF ALL SHAREHOLDERSMIAMI, May 21, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perp
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRDOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira BiosciencesIndependent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive ChangeIntend to Work Collaboratively with Incumbent Directors to Strengthen Oversight and Create Value for All ShareholdersEncourage Shareholders to Support Meaningful Board Change by Voting via the WHITE Proxy Card for DOMA's Three NomineesMIAMI, May 20, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual") which, together with its affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ:PCRX) ("Pacira" or the "Company") an
- PRPacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All StockholdersUrges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, recently posted an investor presentation in connection with its upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled to be held on June 9, 2026. Stockholders of record as of April 22, 2026 are entitled to vote at the Annual Meeting. The presentation is available on the Pacira website at investor.pacira.com. Highl
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRDOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board CandidatesDOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of the Board's Duty of CareMaintains the Company should remove its CEO and Explore a Strategic Sale of the Company Instead of Pursuing Risky LitigationAsserts Pacira Will Continue its Value-Destroying Behavior Unless Changes are Made to the Board; DOMA's Nominees Will Bring Relevant Expertise in Risk Management and Commitment to Stockholder Value to Realign the Board with Shareholders' Interests and Creating Certainty in Outcomes Instead of Gambling with the Company's FutureMIAMI, May 13, 2026 /PRNew
- PRPacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare ConferencesBRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences: 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th at 8:30AM ET.2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 9:55AM ET.Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8th at 1:20PM ET. Live audio of the events can be accessed by visiting the "Events" page of the company's website at i
PCRX FAQ
7 questionsWhat does Pacira BioSciences Inc. do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver...Where does PCRX stock trade?
Pacira BioSciences Inc. (PCRX) is listed on NASDAQ.What sector and industry is PCRX in?
Pacira BioSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pacira BioSciences Inc. go public?
Pacira BioSciences Inc. (PCRX) completed its IPO in 2011.What are analysts saying about PCRX?
Pacira BioSciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $2700.00 price target on 2025-12-09. Recent price targets range from $800.00 to $3000.00.What companies are similar to PCRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PCRX side-by-side with any of them on Quantisnow.How can I track PCRX on Quantisnow?
Quantisnow aggregates Pacira BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCRX to receive live email and push alerts on every new disclosure.